Analyst calls Orphazyme's 300 percent value jump "strange and noteworthy"
Danish biotech company Orphazyme experienced a dramatic value increase on the US stock exchange on Thursday, with trading of the share suspended 20 times. Nordnet analyst Per Hansen calls the increase illogical.
BY RITZAU, TRANSLATED BY CATHERINE BRETT
On Thursday, Danish biotech company Orphazyme experienced a dramatic value jump on the US stock exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
